Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antihyperglycemic agents from Wyeth-Ayerst

Sep. 27, 1996

Takeda's pipeline of metabolic drugs

Sep. 27, 1996

Orphan drug finally approved for urea cycle disorders

Sep. 27, 1996

Tularik-Japan Tobacco leptin gene collaboration

Sep. 27, 1996

Lilly's antiobesity proteins

Sep. 27, 1996

Hypocholesterolemic and hypocholesterolemic/antioxidant compounds from Pierre Fabre

Sep. 27, 1996

Takeda reports new agent for improving lipid metabolism

Sep. 27, 1996

Nippon Shoji's newest ACAT inhibitors

Sep. 27, 1996

Kyowa Hakko describes protein inducing osteoblast proliferation

Sep. 27, 1996

New tocolytics from Merck & Co.

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.